202 related articles for article (PubMed ID: 37532064)
1. Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.
Yang L; Shu P; Wu N; Hu M; Luo Z
Eur J Pharm Sci; 2023 Oct; 189():106552. PubMed ID: 37532064
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
[TBL] [Abstract][Full Text] [Related]
3. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
5. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X
Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study.
Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects.
Li N; Du S; Wang Y; Zhu X; Shu S; Men Y; He M; Fang F; Wang Y; Gong Y; Chen J; Gu L; Cheng Y; He Q; Lu H; Niu Y; Xu Y; Feng P
Eur J Pharm Sci; 2022 Sep; 176():106257. PubMed ID: 35820629
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.
Hall J; Gillen M; Liu S; Miner JN; Valdez S; Shen Z; Lee C
Drug Des Devel Ther; 2018; 12():1799-1807. PubMed ID: 29950814
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
Maher TM; van der Aar EM; Van de Steen O; Allamassey L; Desrivot J; Dupont S; Fagard L; Ford P; Fieuw A; Wuyts W
Lancet Respir Med; 2018 Aug; 6(8):627-635. PubMed ID: 29792287
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects.
Jin J; Cui G; Mi N; Wu W; Zhang X; Xiao C; Wang J; Qiu X; Han M; Li Z; Wang L; Lu T; Niu H; Wu Z; Li J
Eur J Pharm Sci; 2023 Jun; 185():106448. PubMed ID: 37062422
[TBL] [Abstract][Full Text] [Related]
15. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
[TBL] [Abstract][Full Text] [Related]
17. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
Richard M; Kaufmann P; Kornberger R; Dingemanse J
Epilepsia; 2019 May; 60(5):968-978. PubMed ID: 31004346
[TBL] [Abstract][Full Text] [Related]
18. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Li R; Jain JP; Lefèvre G; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Oct; 58(10):6209-14. PubMed ID: 25114127
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
